Despite recent progress and therapeutic advances made in the field of breast cancer. This pathology remains the main cause of female cancer and repre-sents a real major public health problem in Algeria as well as globally. The objective of this study, carried out in the Algerian West, was to assess the epidemiological profile of breast cancer in the Oran region through the pa-tients recruited in the Regional Military Hospital of Oran University (HMRUO), then to determine the clinical, biological and pathological factors that conditioned the overall survival. Among the methodological approaches used in our study were classical histology, immunohistochemistry and fluo-rescence in situ hybridization (FISH) techniques of different biological mar-kers (HER2, hormone receptors (RE and RP). The analysis is carried out using the Epi Info software version 3.4 on all invasive cancers. In a retrospective study of 265 patients with breast cancer over 3 years (February 2017–October 2019), we examined the epidemiological profile of breast cancer to determine the impact of biological and prognostic factors on survival over 3 years. Invasive tumours were found in 95.5% of the women. The average tumour size was big [3.6 (SD 2.6) cm] and only 14% were histological grade I. Overall survival at 3 years was only 49% for the RE–/RP–/HER2– subtype and 75% for the RE–/RP–/HER2+ subtype, while it was 96% for the RE+/RP+/HER2– subtype. The young age, large tumour size and high histological grade in our population suggest a lack of awareness of women about breast can-cer.

Breast cancer represents the most common malignant tumor afflicting women. This pathological condition remains the leading cause of death which constitutes an affliction that deserves considerable attention. As a result, the potential implication of viruses in its pathogenesis remains worth a hypothesis. The potential role of Epstein-Barr virus (EBV) in its pathogenesis is still a subject of continued discussion and investigations. The aim of this study is to evaluate a possible association between EBVs in breast cancers in western Algeria, and to determine the clinicopathological characteristics in order to specify the clinicopathological profile of tumors associated with this virus. We have searched the presence of EBV in 60 human breast cancer samples thanks to different techniques such as: PCR, in situ hybridization of EBER sequences and immunohistochemistry for latent membrane protein 1 (LMP1). The results obtained from this study showed the presence of this virus in only 16 cases or 26.6%. While the remaining 44 samples with a percentage of 73.3% showed a negative value. This may be due to sensitivity in the different techniques used and also what prompts us to suggest resuming the study using much more sensitive techniques such as real-time PCR. Our study indicates the presence of EBV DNA in a significant proportion of breast cancer in western Algeria. Further studies are required to clarify the role of this virus in breast carcinogenesis.

Introduction: Breast carcinoma is a heterogeneous pathology. These subtypes are known to vary in terms of risk factors, natural histories and responses to therapies. The prognostic classification based on gene expression and genomic profiling was implemented to refine therapeutic indications and improve patient survival. Our goal is to classify infiltrating channel carcinomas according to their molecular profiles and analyze the different clinicopathological variables of these molecular groups. Material and methods: We conducted a 24-month retrospective study involving 50 patients recruited from the Oran University Hospital and the Oran Regional Military Hospital. Tumors were analyzed histologically and classified after an immunohistochemical study in groups: luminal A, luminal B, Her2+ and basal-like. Results: Our study showed the predominance of molecular subtype luminal B (36%) of which 55.56% of these tumors were of Scarff-Bloom-Richardson (SBR) grade II and 44% were of grade III. 55.56% were T2 size followed by T1 size with a percentage of about 33.33%. Axillary ganglionic metastases were found in 88.89% of cases, followed by luminal A (32%) with 62.5% grade III, and 37.5% grade SBR II. Thus 37.5% of these tumors were of stage T2 and T4. Axillary ganglionic metastases were present in 87.5%. The HER2 type (20%) with 60% SBR II grade and 40% grade III. All basal-like tumors represented the highest SBR grade III with a percentage of 100%. Conclusions: Molecular classification is crucial in the direction of treatment.